Presentations / 4th Molecular Diagnostics For Cancer Drug Development by Hanson Wade

KEYNOTE ADDRESS: Where we are Now: Development, Approval and Commercialization of CDx in Oncology

Companion Diagnostics: FDA Policies on Oversight

Deciding when a Targeted Drug is Ready to Leave Phase I: An Academic Perspective

Developing a Successful Strategy for Targeted Therapy Development in Oncology: Key Considerations

Case Study: Identifying a Predictive Biomarker of Response to Imetelstat, a Telomerase Inhibitor

From Research Lab to a Validated Biomarker Assay that Improves Therapy: What the Researcher Needs to Consider

Identification of Response Biomarkers and Development of Clinical Assays for Patient Stratification: A Case Study

Identification of Stratification Biomarkers for Cancer Management

Molecular Pathology in Decision Making for Clinical Drug Development

Evolving from a Biomarker to a Companion Diagnostic

Enabling Reliable Mutational Profiling of Clinical Samples: COLD-PCR Technology and Application to Highly Sensitive Sequencing

Pioneering Partnerships: Business Models for Successful Companion Diagnostic Co Development

Molecular Diagnostics: Challenges, Opportunities, Vision and Longevity

Evolving Applications of Oncology Clinical Trial Specimens and Externaln Biorepositories for Biomarker and Diagnostic Development

Acquiring and Using your own Clinical Trial Specimens for Biomarker Identification

Biospecimen Challenges in Developing and Validating Molecular Diagnostic Assays

Next Generation Sequencing of Cancer-Associated Genes in FFPE Tumor DNA

Successful MDx Development: Tissue is the Issue

Aligning the Development, Regulatory and Commercial Strategies for a Companion Diagnostic

Reimbursement for Personalized Medicine Diagnostics: Current Limitations and Evolving Strategies